

**Precision Diagnostics & Medicine Market by Diagnostic Testing (Genetic, DTC),
Diagnostics Indication (Oncology, Neurology, Immunology), Therapeutic Products
(Inhibitors, mAbs, CGT), Indication (Oncology, Rare Disease, Infectious) - Global
Forecast to 2029**

Market Report | 2025-01-21 | 446 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The global Precision Diagnostics and Medicine market is projected to reach USD 246.66 billion in 2029 from USD 145.53 billion by 2024, at a CAGR of 11.1% during the forecast period. Factors such as the ongoing integration of advanced technologies such as artificial intelligence and machine learning to enhance precision medicine development, supported by the rising collaboration and investments by major pharmaceutical and diagnostics companies to develop better precision medicine solutions are supporting the growth of the market. Moreover, the expanding focus of these companies to develop precision therapies and diagnostic tests for multiple diseases such as neurodegenerative and autoimmune diseases highlight the growing importance of precision medicine in healthcare. Additionally, the increasing awareness of patients regarding their health is supporting the adoption of wearable medical devices and direct-to-consumer precision diagnostic tests offering growth opportunities to players in this market. However, the high cost of precision healthcare and challenges associated with the integration and management of big data in healthcare are expected to restrain the growth of this market.

"The monoclonal antibodies segment registered the highest growth rate in the precision medicine market, by products, during the forecast period"

In 2023, the monoclonal antibodies segment registered the highest growth rate within the precision medicine market by products. Factors such as the increasing collaborations to develop advanced monoclonal antibodies and advancements in antibody engineering technologies are attributed to the growth of this segment. Additionally, these modalities offer various advantages over traditional drugs such as high specificity, low toxicity, and longer-lasting effects among others increasing the adoption of these drug modalities for the treatment of cancer, autoimmune, and infectious diseases supporting the growth of this segment.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com

"The hospitals and clinics end user segment registered the highest growth rate and largest market share in the precision medicine market, by end user, during the forecast period"

The hospitals and clinic end users registered the highest growth rate within the precision medicine market by end user segment during the forecast period. Factors such as the growing demand for personalized treatments and the ability of hospitals and clinics to offer personalized therapies in a controlled environment can be attributed to the large share of this end user segment. Moreover, the rising collaborations between hospitals and pharmaceutical and diagnostic companies to develop personalized therapies and diagnostic tests support the growth of this segment. Hospitals and clinics act as data reservoirs for these companies which gather real-world data from these institutions for the development of advanced precision solutions. This high growth is projected to continue during the forecast period.

"Asia Pacific: The fastest growing region in the Precision Diagnostics market"

The precision diagnostics market of Asia Pacific is projected to register the highest growth rate during the forecast period. This high growth is attributed to the rising cases of chronic diseases, cancer, and genetic disorders in this region leading to a growing demand for precision diagnostics solutions. This growth is supported by investments in healthcare infrastructure across countries like China, India, and Japan, enhancing access to advanced diagnostic technologies. Additionally, the adoption of technologies like next-generation sequencing (NGS), artificial intelligence, and machine learning is driving innovations in the field. Government initiatives and improved healthcare coverage also contribute to expanding access to precision diagnostics. Moreover, the support and funding from government organizations for life sciences research and development also support the rapid growth of the Asia Pacific precision diagnostics market.

The primary interviews conducted for this report can be categorized as follows:

- By Company Type: Tier 1 - 44%, Tier 2 - 32%, and Tier 3 - 24%
- By Designation: (Managers) - 45%, (CXOs, Directors)- 30%, and(Executives) - 25%
- By Region: North America -40%, Europe -25%, Asia-Pacific -20%, ROW -15%

List of Companies Profiled in the Report:

- Merck & Co., Inc. (US)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Agilent Technologies, Inc. (US)
- Thermo Fisher Scientific Inc. (US)
- Myriad Genetics, Inc. (US)
- Guardant Health (US)
- Abbott (US)
- Natera Inc. (US)
- Illumina, Inc. (US)
- Danaher (US)
- Exact Sciences Corporation (US)
- Qiagen (Netherlands)
- 23andME, INC. (US)
- ARUP Laboratories. (US)
- Devyser (Sweden)
- Diasorin S.P.A. (Italy)
- Tempus (US)
- Pillar Biosciences Inc. (US)
- Invivoscribe, Inc. (US)
- NeuroCode (US)
- C?N Diagnostics (US)
- Trinity Biotech Plc. (Ireland)
- Amoy Diagnostics Co., Ltd. (China)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- [] Novartis AG (Switzerland)
- [] Bristol-Myers Squibb Company (US)
- [] Gilead Sciences, Inc. (US)
- [] AstraZeneca (UK)
- [] AbbVie Inc. (US)
- [] Eli Lilly and Company. (US)
- [] Pfizer Inc. (US), GSK plc. (UK)
- [] Sanofi (France)
- [] Johnson & Johnson Services, Inc. (US)
- [] Vertex Pharmaceuticals Incorporated (US)
- [] Amgen Inc. (US)
- [] Merck KGaA (Germany)
- [] Sarepta Therapeutics, Inc. (US).

Research Coverage:

This report provides a detailed picture of the global Precision Diagnostics and Medicine Market. It aims to estimate the size and future growth potential of the market across different segments such as the precision diagnostics market (type, indication, and end user) and precision medicine market (product, indication, and end user) region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the precision diagnostics and medicine market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements, new product launches, mergers and acquisitions, and recent developments associated with the precision diagnostics and medicine market. Competitive analysis of upcoming startups in the precision diagnostics and medicine market ecosystem is covered in this report.

Reasons to buy this report :

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall precision diagnostics and medicine market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

- [] Analysis of key drivers (Increasing Integration Of AI And ML To Improve Precision Diagnostics And Therapy Development, Rising Collaborations Between Pharmaceutical And Diagnostics Company To Enhance Precision Healthcare and Rise in direct-to-consumer testing), restraints (High costs of precision healthcare and Slow Pace Of Reimbursement For Precision Diagnostics), opportunities (Expanding The Application Of Precision Diagnostics From Oncology and Integration of wearable devices to enhance precision healthcare), and challenges (Challenges in Regulatory Approval for Diagnostics and Big Data Management and Integration) influencing the growth of the precision diagnostics and medicine market.
- [] Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches and approvals in the precision diagnostics and medicine market
- [] Market Development: Comprehensive information about lucrative markets - the report analyses the precision diagnostics and medicine market across varied regions.
- [] Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the precision diagnostics and medicine market
- [] Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players in precision diagnostics market like- F. Hoffmann-La Roche Ltd. (Switzerland), Abbott (US), Agilent Technologies, Inc. (US), Guardant Health (US), Thermo Fisher Scientific Inc. (US), Myriad Genetics, Inc. (US) among others and precision medicine market like- Merck & Co., Inc. (US), Bristol-Myers Squibb Company (US) Gilead Sciences, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), AstraZeneca (UK), Novartis AG (Switzerland), among others.

Table of Contents:

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

1	INTRODUCTION	34
1.1	STUDY OBJECTIVES	34
1.2	MARKET DEFINITION	34
1.3	STUDY SCOPE	35
1.3.1	MARKETS COVERED AND REGIONAL SCOPE	35
1.3.2	INCLUSIONS AND EXCLUSIONS	36
1.3.3	YEARS CONSIDERED	37
1.4	CURRENCY CONSIDERED	37
1.5	STAKEHOLDERS	37
1.6	SUMMARY OF CHANGES	38
2	RESEARCH METHODOLOGY	39
2.1	RESEARCH DATA	39
2.1.1	SECONDARY DATA	40
2.1.2	PRIMARY DATA	40
2.2	MARKET SIZE ESTIMATION METHODOLOGY	41
2.2.1	PRECISION DIAGNOSTICS MARKET	41
2.2.2	PRECISION MEDICINE MARKET	44
2.2.3	INSIGHTS FROM PRIMARY SOURCES	46
2.3	TOP-DOWN APPROACH	47
2.3.1	PRECISION DIAGNOSTICS MARKET	47
2.3.2	PRECISION MEDICINE MARKET	48
2.4	GROWTH FORECAST MODEL	49
2.5	MARKET BREAKDOWN AND DATA TRIANGULATION	51
2.6	RESEARCH ASSUMPTIONS	52
2.7	RESEARCH LIMITATIONS	52
2.8	RISK ANALYSIS	52
3	EXECUTIVE SUMMARY	53
4	PREMIUM INSIGHTS	58
4.1	PRECISION DIAGNOSTICS MARKET OVERVIEW	58
4.2	PRECISION MEDICINE MARKET OVERVIEW	59
4.3	NORTH AMERICA: PRECISION DIAGNOSTICS MARKET, BY TYPE AND COUNTRY, 2023	60
4.4	PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2024 VS. 2029	60
4.5	PRECISION DIAGNOSTICS MARKET, BY END USER, 2023	61
4.6	NORTH AMERICA: PRECISION MEDICINE MARKET, BY PRODUCT AND COUNTRY, 2023	61
4.7	PRECISION MEDICINE MARKET, BY INDICATION, 2024 VS. 2029	62
4.8	PRECISION DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES	62
4.9	PRECISION MEDICINE MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES	63
5	MARKET OVERVIEW	64
5.1	INTRODUCTION	64
5.2	MARKET DYNAMICS	64
5.2.1	DRIVERS	65
5.2.1.1	Increasing collaborations between pharmaceutical and diagnostic companies	65
5.2.1.2	Rise in direct-to-consumer testing	66
5.2.1.3	Growing integration of artificial intelligence and machine learning	66
5.2.2	RESTRAINTS	67
5.2.2.1	High cost of precision healthcare	67
5.2.3	OPPORTUNITIES	67

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.2.3.1	Expanding applications of precision healthcare	67
5.2.3.2	Growing adoption of wearable devices	68
5.2.4	CHALLENGES	68
5.2.4.1	Complex regulatory approval landscape	68
5.2.4.2	Big data management and integration issues	69
5.3	TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS	69
5.4	PRICING ANALYSIS	70
5.4.1	AVERAGE SELLING PRICE TREND, BY KEY PLAYER	70
5.4.2	AVERAGE SELLING PRICE TREND OF PRECISION MEDICINE PRODUCTS, BY KEY PLAYER	72
5.4.3	AVERAGE SELLING PRICE TREND, BY REGION	73
5.5	VALUE CHAIN ANALYSIS	74
5.5.1	PRECISION DIAGNOSTICS MARKET	74
5.5.2	PRECISION MEDICINE MARKET	76
5.6	SUPPLY CHAIN ANALYSIS	77
5.6.1	PRECISION DIAGNOSTICS MARKET	77
5.6.2	PRECISION MEDICINE MARKET	78
5.7	ECOSYSTEM ANALYSIS	79
5.8	PIPELINE ANALYSIS	81
5.9	DIAGNOSTIC PRODUCT ANALYSIS	83
5.10	INVESTMENT/FUNDING ACTIVITY	96
5.11	TECHNOLOGY ANALYSIS	97
5.11.1	KEY TECHNOLOGIES	97
5.11.1.1	Next-generation sequencing	97
5.11.1.2	Immunohistochemistry	97
5.11.1.3	Liquid biopsy	97
	?	
5.11.2	COMPLEMENTARY TECHNOLOGIES	98
5.11.2.1	Single-cell analysis	98
5.11.2.2	AI and ML integration	98
5.11.3	ADJACENT TECHNOLOGIES	98
5.11.3.1	Theranostics	98
5.11.3.2	Imaging technologies	99
5.12	PATENT ANALYSIS	99
5.13	TRADE ANALYSIS	102
5.13.1	IMPORT DATA	102
5.13.2	EXPORT DATA	104
5.14	KEY CONFERENCES AND EVENTS, 2025-2026	106
5.15	REGULATORY LANDSCAPE	107
5.15.1	REGULATORY ANALYSIS	107
5.15.1.1	North America	107
5.15.1.2	Europe	108
5.15.1.3	Asia Pacific	108
5.15.1.4	Rest of the World	108
5.15.2	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	109
5.16	PORTER'S FIVE FORCES ANALYSIS	112
5.16.1	PRECISION DIAGNOSTICS MARKET	112
5.16.1.1	Threat of new entrants	113

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.16.1.2	Threat of substitutes	113
5.16.1.3	Bargaining power of buyers	114
5.16.1.4	Bargaining power of suppliers	114
5.16.1.5	Intensity of competitive rivalry	114
5.16.2	PRECISION MEDICINE MARKET	114
5.16.2.1	Threat of new entrants	115
5.16.2.2	Threat of substitutes	115
5.16.2.3	Bargaining power of buyers	115
5.16.2.4	Bargaining power of suppliers	116
5.16.2.5	Intensity of competitive rivalry	116
5.17	KEY STAKEHOLDERS AND BUYING CRITERIA	116
5.17.1	KEY STAKEHOLDERS IN BUYING PROCESS	116
5.17.2	BUYING CRITERIA	119
5.18	IMPACT OF AI/GEN AI ON PRECISION DIAGNOSTICS AND MEDICINE MARKET	121
5.18.1	INTRODUCTION	121
5.18.2	MARKET POTENTIAL OF PRECISION DIAGNOSTICS AND MEDICINES	121
5.18.3	AI USE CASES	122
5.18.4	KEY COMPANIES IMPLEMENTING AI	123
5.18.5	FUTURE OF GENERATIVE AI ON PRECISION DIAGNOSTICS AND MEDICINE ECOSYSTEM	123
6	PRECISION DIAGNOSTICS MARKET, BY TYPE	124
6.1	INTRODUCTION	125
6.2	GENETIC TESTING	125
6.2.1	NEED TO DETECT HEREDITARY AND RARE DISEASES TO STIMULATE GROWTH	125
6.3	DTC TESTING	127
6.3.1	INCREASED AWARENESS ABOUT PERSONALIZED HEALTH TO ENCOURAGE GROWTH	127
6.4	OTHER TYPES	130
7	PRECISION DIAGNOSTICS MARKET, BY INDICATION	132
7.1	INTRODUCTION	133
7.2	ONCOLOGY	133
7.2.1	RISING CANCER CASES TO ACCELERATE GROWTH	133
7.3	NEUROLOGY	136
7.3.1	INCREASING DEVELOPMENT OF PRECISION DIAGNOSTIC TESTS FOR NEUROLOGICAL DISEASES TO FUEL MARKET	136
7.4	IMMUNOLOGY	138
7.4.1	GROWING INTEGRATION OF ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN DIAGNOSTIC TOOLS TO DRIVE MARKET	138
7.5	OTHER DIAGNOSTIC INDICATIONS	140
8	PRECISION DIAGNOSTICS MARKET, BY END USER	143
8.1	INTRODUCTION	144
8.2	CLINICAL LABORATORIES	144
8.2.1	RISING DEMAND FOR PERSONALIZED MEDICINE TO FACILITATE GROWTH	144
8.3	HOSPITALS	146
8.3.1	GROWING COLLABORATIONS AMONG DIAGNOSTIC MANUFACTURING COMPANIES TO DRIVE MARKET	146
8.4	HOME CARE SETTINGS	148
8.4.1	INCREASING DEMAND FOR AT-HOME DIAGNOSTIC TESTS TO SPUR GROWTH	148
9	PRECISION MEDICINE MARKET, BY PRODUCT	151
9.1	INTRODUCTION	152

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

9.2	MONOCLONAL ANTIBODIES	152
9.2.1	RISING ADOPTION OF ONCOLOGY AND AUTOIMMUNE THERAPIES TO SUPPORT GROWTH	152
9.3	INHIBITOR DRUGS	154
9.3.1	INCREASING FDA APPROVALS FOR NOVEL INHIBITORS TO CONTRIBUTE TO GROWTH	154
9.4	CELL & GENE THERAPIES	157
9.4.1	GROWING INVESTMENTS IN GENETIC DISORDER RESEARCH TO FUEL MARKET	157
9.5	ANTIVIRAL & ANTI-RETROVIRAL DRUGS	159
9.5.1	NEED TO TARGET VIRAL INFECTIONS AND PREVENT VIRUS SPREAD TO FACILITATE GROWTH	159
9.6	OTHER PRODUCTS	161
10	PRECISION MEDICINE MARKET, BY INDICATION	164
10.1	INTRODUCTION	165
10.2	ONCOLOGY	165
10.2.1	GROWING EMPHASIS ON DEVELOPING PRECISION CANCER THERAPIES TO BOOST MARKET	165
10.3	RARE DISEASES	167
10.3.1	SHIFTING FOCUS ON TARGETED TREATMENT TO FAVOR GROWTH	167
10.4	INFECTIOUS DISEASES	170
10.4.1	NEED TO ENHANCE EFFICACY OF TREATMENTS TO DRIVE MARKET	170
10.5	HEMATOLOGICAL DISORDERS	172
10.5.1	INCREASING RESEARCH ON DEVELOPING PERSONALIZED THERAPIES TO AUGMENT GROWTH	172
10.6	OTHER MEDICINE INDICATIONS	174
11	PRECISION MEDICINE MARKET, BY END USER	177
11.1	INTRODUCTION	178
11.2	HOSPITALS & CLINICS	178
11.2.1	GROWING FOCUS ON PRECISION THERAPIES TO FUEL MARKET	178
11.3	HOME CARE SETTINGS	180
11.3.1	INCREASING PREFERENCE FOR SELF-ADMINISTRATION TECHNIQUES TO EXPEDITE GROWTH	180
12	PRECISION DIAGNOSTICS AND MEDICINE MARKET, BY REGION	183
12.1	INTRODUCTION	184
12.2	NORTH AMERICA	184
12.2.1	MACROECONOMIC OUTLOOK FOR NORTH AMERICA	188
12.2.2	US	189
12.2.2.1	Well-established infrastructure and availability of advanced treatments to augment growth	189
12.2.3	CANADA	191
12.2.3.1	Growing cancer burden to support growth	191
12.3	EUROPE	194
12.3.1	MACROECONOMIC OUTLOOK FOR EUROPE	198
12.3.2	GERMANY	199
12.3.2.1	Growing collaborations between research institutions and healthcare providers to boost market	199
12.3.3	UK	201
12.3.3.1	Favorable government support to expedite growth	201
12.3.4	FRANCE	204
12.3.4.1	Growing preference for personalized medicine to fuel market	204
12.3.5	ITALY	206
12.3.5.1	Rise in genomics research and diagnostic testing to foster growth.	206
12.3.6	SPAIN	208
12.3.6.1	Robust network of healthcare systems, research centers, and universities to facilitate growth	208

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

12.3.7	REST OF EUROPE	211
12.4	ASIA PACIFIC	213
12.4.1	MACROECONOMIC OUTLOOK FOR ASIA PACIFIC	216
12.4.2	CHINA	217
12.4.2.1	Growing regulatory approvals for precision medicines to boost market	217
12.4.3	JAPAN	219
12.4.3.1	Increasing availability of health insurance to encourage growth	219
12.4.4	INDIA	222
12.4.4.1	Rising burden of chronic diseases to promote growth	222
12.4.5	AUSTRALIA	224
12.4.5.1	Booming research & development investments to spur growth	224
12.4.6	REST OF ASIA PACIFIC	226
12.5	LATIN AMERICA	228
12.5.1	MACROECONOMIC OUTLOOK FOR LATIN AMERICA	231
12.5.2	BRAZIL	232
12.5.2.1	Growing incorporation of genomic medicine into public healthcare to drive market	232
12.5.3	MEXICO	235
12.5.3.1	Booming biopharmaceutical sector to contribute to growth	235
12.5.4	REST OF LATIN AMERICA	237
12.6	MIDDLE EAST & AFRICA	239
12.6.1	MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA	242
13	COMPETITIVE LANDSCAPE	244
13.1	OVERVIEW	244
13.2	KEY PLAYER STRATEGIES/RIGHT TO WIN, 2021-2024	244
13.2.1	PRECISION DIAGNOSTICS MARKET	244
13.2.2	PRECISION MEDICINE MARKET	247
13.3	REVENUE ANALYSIS, 2021-2023	252
13.3.1	PRECISION DIAGNOSTICS MARKET	252
13.3.2	PRECISION MEDICINE MARKET	253
13.4	MARKET SHARE ANALYSIS, 2023	254
13.4.1	PRECISION DIAGNOSTICS MARKET	254
13.4.2	PRECISION MEDICINE MARKET	257
?		
13.5	COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023	260
13.5.1	PRECISION DIAGNOSTICS MARKET	260
13.5.1.1	Stars	260
13.5.1.2	Emerging leaders	260
13.5.1.3	Pervasive players	260
13.5.1.4	Participants	261
13.5.1.5	Company footprint: Key players, 2023	262
13.5.1.5.1	Company footprint	262
13.5.1.5.2	Region footprint	263
13.5.1.5.3	Type footprint	264
13.5.1.5.4	Indication footprint	265
13.5.2	PRECISION MEDICINE MARKET	266
13.5.2.1	Stars	267
13.5.2.2	Emerging leaders	267

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

13.5.2.3	Pervasive players	267
13.5.2.4	Participants	267
13.5.2.5	Company footprint: Key players, 2023	269
13.5.2.5.1	Company footprint	269
13.5.2.5.2	Region footprint	270
13.5.2.5.3	Product footprint	271
13.5.2.5.4	Indication footprint	272
13.6	COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023	274
13.6.1	PRECISION DIAGNOSTICS MARKET	274
13.6.1.1	Progressive companies	274
13.6.1.2	Responsive companies	274
13.6.1.3	Dynamic companies	274
13.6.1.4	Starting blocks	274
13.6.1.5	Competitive benchmarking	276
13.6.1.5.1	Detailed list of key startups/SMES	276
13.6.1.5.2	Competitive benchmarking of startups/SMEs	277
13.6.2	PRECISION MEDICINE MARKET	278
13.6.2.1	Progressive companies	278
13.6.2.2	Responsive companies	278
13.6.2.3	Dynamic companies	278
13.6.2.4	Starting blocks	278
13.6.2.5	Competitive benchmarking	280
13.6.2.5.1	Detailed list of key startups/SMES	280
13.6.2.5.2	Competitive benchmarking of startups/SMEs	281
13.7	COMPANY VALUATION AND FINANCIAL METRICS	282
13.7.1	PRECISION DIAGNOSTICS MARKET	282
13.7.2	PRECISION MEDICINE MARKET	283
?		
13.8	BRAND/PRODUCT COMPARISON	284
13.9	PRECISION DIAGNOSTICS MARKET: COMPETITIVE SCENARIO	285
13.9.1	PRODUCT LAUNCHES AND APPROVALS	286
13.9.2	DEALS	287
13.9.3	EXPANSIONS	288
13.10	PRECISION MEDICINE MARKET: COMPETITIVE SCENARIO	288
13.10.1	PRODUCT LAUNCHES AND APPROVALS	289
13.10.2	DEALS	290
13.10.3	EXPANSIONS	291
14	COMPANY PROFILES	292
14.1	KEY PLAYERS	292
14.1.1	F. HOFFMANN-LA ROCHE LTD (DIAGNOSTICS)	292
14.1.1.1	Business overview	292
14.1.1.2	Products offered	293
14.1.1.3	Recent developments	297
14.1.1.3.1	Product launches and approvals	297
14.1.1.3.2	Deals	298
14.1.1.4	MnM view	299
14.1.1.4.1	Key strengths	299

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

14.1.1.4.2	Strategic choices	299
14.1.1.4.3	Weaknesses and competitive threats	299
14.1.2	ABBOTT	300
14.1.2.1	Business overview	300
14.1.2.2	Products offered	301
14.1.2.3	Recent developments	302
14.1.2.3.1	Deals	302
14.1.2.4	MnM view	303
14.1.2.4.1	Key strengths	303
14.1.2.4.2	Strategic choices	303
14.1.2.4.3	Weaknesses and competitive threats	303
14.1.3	AGILENT TECHNOLOGIES, INC.	304
14.1.3.1	Business overview	304
14.1.3.2	Products offered	305
14.1.3.3	Recent developments	307
14.1.3.3.1	Product launches and approvals	307
14.1.3.3.2	Deals	308
14.1.3.3.3	Expansions	308
14.1.3.4	MnM view	308
14.1.3.4.1	Key strengths	308
14.1.3.4.2	Strategic choices	309
14.1.3.4.3	Weaknesses and competitive threats	309
14.1.4	GUARDANT HEALTH	310
14.1.4.1	Business overview	310
14.1.4.2	Products offered	311
14.1.4.3	Recent developments	312
14.1.4.3.1	Product launches and approvals	312
14.1.4.3.2	Deals	314
14.1.4.4	MnM view	315
14.1.4.4.1	Key strengths	315
14.1.4.4.2	Strategic choices	315
14.1.4.4.3	Weaknesses and competitive threats	315
14.1.5	EXACT SCIENCES CORPORATION	316
14.1.5.1	Business overview	316
14.1.5.2	Products offered	317
14.1.5.3	Recent developments	318
14.1.5.3.1	Product launches and approvals	318
14.1.5.3.2	Deals	319
14.1.5.4	MnM view	319
14.1.5.4.1	Key strengths	319
14.1.5.4.2	Strategic choices	319
14.1.5.4.3	Weaknesses and competitive threats	319
14.1.6	QIAGEN	320
14.1.6.1	Business overview	320
14.1.6.2	Products offered	321
14.1.6.3	Recent developments	324
14.1.6.3.1	Product launches and approvals	324

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 14.1.6.3.2 Deals 325
- 14.1.7 MYRIAD GENETICS, INC. 326
 - 14.1.7.1 Business overview 326
 - 14.1.7.2 Products offered 327
 - 14.1.7.3 Recent developments 329
 - 14.1.7.3.1 Product launches and approvals 329
 - 14.1.7.3.2 Deals 329
 - 14.1.7.3.3 Other developments 330
- 14.1.8 NATERA, INC. 331
 - 14.1.8.1 Business overview 331
 - 14.1.8.2 Products offered 332
 - 14.1.8.3 Recent developments 334
 - 14.1.8.3.1 Product launches and approvals 334
 - 14.1.8.3.2 Deals 334
- 14.1.9 ILLUMINA, INC. 335
 - 14.1.9.1 Business overview 335
 - 14.1.9.2 Products offered 336
 - 14.1.9.3 Recent developments 337
 - 14.1.9.3.1 Product launches and approvals 337
 - 14.1.9.3.2 Deals 337
- 14.1.10 THERMO FISHER SCIENTIFIC INC. 339
 - 14.1.10.1 Business overview 339
 - 14.1.10.2 Products offered 340
 - 14.1.10.3 Recent developments 341
 - 14.1.10.3.1 Product launches and approvals 341
 - 14.1.10.3.2 Deals 342
- 14.1.11 DANAHER 344
 - 14.1.11.1 Business overview 344
 - 14.1.11.2 Products offered 345
 - 14.1.11.3 Recent developments 348
 - 14.1.11.3.1 Product launches and approvals 348
 - 14.1.11.3.2 Deals 349
- 14.1.12 23ANDME, INC. 350
 - 14.1.12.1 Business overview 350
 - 14.1.12.2 Products offered 351
 - 14.1.12.3 Recent developments 353
 - 14.1.12.3.1 Deals 353
- 14.1.13 MERCK & CO., INC. 354
 - 14.1.13.1 Business overview 354
 - 14.1.13.2 Products offered 355
 - 14.1.13.3 Recent developments 356
 - 14.1.13.3.1 Product launches and approvals 356
 - 14.1.13.3.2 Deals 360
- 14.1.14 GILEAD SCIENCES, INC. 361
 - 14.1.14.1 Business overview 361
 - 14.1.14.2 Products offered 362
 - 14.1.14.3 Recent developments 364

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 14.1.14.3.1 Product launches and approvals 364
- 14.1.14.3.2 Deals 365
- 14.1.15 F. HOFFMANN-LA ROCHE LTD (MEDICINE) 367
- 14.1.15.1 Business overview 367
- 14.1.15.2 Products offered 368
- 14.1.15.3 Recent developments 371
- 14.1.15.3.1 Product launches and approvals 371
- 14.1.16 BRISTOL-MYERS SQUIBB COMPANY 373
- 14.1.16.1 Business overview 373
- 14.1.16.2 Products offered 374
- 14.1.16.3 Recent developments 376
- 14.1.16.3.1 Product launches and approvals 376
- 14.1.16.3.2 Deals 378
- 14.1.17 NOVARTIS AG 379
- 14.1.17.1 Business overview 379
- 14.1.17.2 Products offered 380
- 14.1.17.3 Recent developments 383
- 14.1.17.3.1 Product launches and approvals 383
- 14.1.17.3.2 Deals 384
- 14.1.18 ASTRAZENECA 386
- 14.1.18.1 Business overview 386
- 14.1.18.2 Products offered 387
- 14.1.18.3 Recent developments 389
- 14.1.18.3.1 Product launches and approvals 389
- 14.1.18.3.2 Deals 390
- 14.1.19 ABBVIE INC. 391
- 14.1.19.1 Business overview 391
- 14.1.19.2 Products offered 392
- 14.1.19.3 Recent developments 393
- 14.1.19.3.1 Product launches and approvals 393
- 14.1.19.3.2 Deals 393
- 14.1.19.3.3 Expansions 394
- 14.1.20 LILLY 395
- 14.1.20.1 Business overview 395
- 14.1.20.2 Products offered 396
- 14.1.20.3 Recent developments 397
- 14.1.20.3.1 Product launches and approvals 397
- 14.1.20.3.2 Deals 398
- 14.1.21 PFIZER INC. 399
- 14.1.21.1 Business overview 399
- 14.1.21.2 Products offered 400
- 14.1.21.3 Recent developments 402
- 14.1.21.3.1 Product launches and approvals 402
- 14.1.21.3.2 Deals 402
- 14.1.22 SAREPTA THERAPEUTICS, INC. 403
- 14.1.22.1 Business overview 403
- 14.1.22.2 Products offered 404

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

14.1.22.3	Recent developments	405
14.1.22.3.1	Product launches and approvals	405
14.1.22.3.2	Deals	406
14.1.23	VERTEX PHARMACEUTICALS INCORPORATED	407
14.1.23.1	Business overview	407
14.1.23.2	Products offered	408
14.1.23.3	Recent developments	409
14.1.23.3.1	Product launches and approvals	409
14.1.23.3.2	Deals	410
14.1.24	GSK PLC.	411
14.1.24.1	Business overview	411
14.1.24.2	Products offered	412
14.1.24.3	Recent developments	413
14.1.24.3.1	Product launches and approvals	413
14.1.24.3.2	Deals	414
14.2	OTHER PLAYERS	416
14.2.1	SANOFI	416
14.2.2	JOHNSON & JOHNSON SERVICES, INC.	417
14.2.3	AMGEN INC.	418
14.2.4	MERCK KGAA	419
14.2.5	ALNYLAM PHARMACEUTICALS, INC.	420
14.2.6	INCYTE	421
14.2.7	ARUP LABORATORIES	422
14.2.8	DEVYSER	423
14.2.9	DIASORIN S.P.A.	424
14.2.10	TEMPUS	426
14.2.11	PILLAR BIOSCIENCES INC.	427
14.2.12	INVIVOSCRIBE, INC.	428
14.2.13	NEUROCODE	429
14.2.14	C?N DIAGNOSTICS	430
14.2.15	TRINITY BIOTECH	431
14.2.16	AMOY DIAGNOSTICS CO., LTD.	432
15	APPENDIX	434
15.1	DISCUSSION GUIDE	434
15.2	KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL	441
15.3	CUSTOMIZATION OPTIONS	443
15.4	RELATED REPORTS	444
15.5	AUTHOR DETAILS	445

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

**Precision Diagnostics & Medicine Market by Diagnostic Testing (Genetic, DTC),
Diagnostics Indication (Oncology, Neurology, Immunology), Therapeutic Products
(Inhibitors, mAbs, CGT), Indication (Oncology, Rare Disease, Infectious) - Global
Forecast to 2029**

Market Report | 2025-01-21 | 446 pages | MarketsandMarkets

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scottis-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scottis-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scottis-international.com

www.scottis-international.com

Zip Code*

Country*

Date

2026-03-02

Signature

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com